New Delhi: In a temporary setback to Wockhardt, the National Pharmaceutical Pricing Authority (NPPA) has sought further clarifications from the drugmaker on its application seeking exemption for the patented, non-scheduled formulation Nafithromycin Tablets under Paragraph 32(i) of the Drugs (Prices Control) Order, 2013 (DPCO, 2013).

The Committee also directed that inputs be obtained from both the Central Drugs Standard Control Organization (CDSCO) and the Office of the Controller General of Patents, Designs and Trade Marks (CGPDTM) to verify whether the formulation approved by CDSCO corresponds to the one covered under the granted patent. It further instructed that the application, along with the required clarifications, be placed before the Committee again for further consideration.

T

See Full Page